CoChat

Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae

Open access

The DOI matches its Crossref record; 56 of the 59 references it cites were found in a registry or an index.

Abstract

Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) may serve as a new assay for drug testing in a human context, but their validity particularly for the evaluation of inotropic drug effects remains unclear. In this blinded analysis, we compared the effects of 10 indicator compounds with known inotropic effects in electrically stimulated (1.5 Hz) hiPSC-CM-derived 3-dimensional engineered heart tissue (EHT) and human atrial trabeculae (hAT). Human EHTs were prepared from iCell hiPSC-CM, hAT obtained at routine heart surgery. Mean intra-batch variation coefficient in baseline force measurement was 17% for EHT and 49% for hAT. The PDE-inhibitor milrinone did not affect EHT contraction force, but increased force in hAT. Citalopram (selective serotonin reuptake inhibitor), nifedipine (LTCC-blocker) and lidocaine (Na+ channel-blocker) had negative inotropic effects on EHT and hAT. Formoterol (beta-2 agonist) had positive lusitropic but no inotropic effect in EHT, and positive clinotropic, lusitropic, and inotropic effects in hAT. Tacrolimus (calcineurin-inhibitor) had a negative inotropic effect in EHTs, but no effect in hAT. Digoxin (Na+-K+-ATPase-inhibitor) showed a positive inotropic effect only in EHTs, but no effect in hAT probably due to short incubation time. Ryanodine (ryanodine receptor-inhibitor) reduced contraction force in both models. Rolipram and acetylsalicylic acid showed noninterpretable results in hAT. Contraction amplitude and kinetics were more stable over time and less variable in hiPSC-EHTs than hAT. HiPSC-EHT faithfully detected cAMP-dependent and -independent positive and negative inotropic effects, but limited beta-2 adrenergic or PDE3 effects, compatible with an immature CM phenotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/toxsci/kfx081

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Quality control of hiPSC-EHTs and hAT in modified Tyrode‘s solution. A, Live image of a 12 days old EHT from hiPSC-CM. B, Baseline contraction force (1.8 mM Ca2+) of spontaneously beating hiPSC-EHTs (n = 66) indicating the threshold value of 0.1 mN was reached for 65 hiPSC-EHTs. C, Calcium concentration–response-curve of hiPSC-EHTs (mean ± SEM; n = 11). D, Concentration–response-curve for isoprenaline (1 mM Ca2+, 2 Hz; n = 11). E, Positive inotropic and lusitropic effect in response to isoprenaline indicated as changes in force and relaxation time (RT; 100 nM; one-way ANOVA, repeated measures, Bonferroni’s post-test, *P < 0.05; n = 11). F, Time course of EHT development depicting contraction force overtime indicating stable EHT contractility starting at day 20 (mean ± SD; n = 12). G, Exemplary original trace of a human atrial trabecula in the organ bath demonstrating Frank–Starling mechanism, stable diastolic tension and robust contractions over initial equilibration period of 90 min.
Figure 1 Quality control of hiPSC-EHTs and hAT in modified Tyrode‘s solution. A, Live image of a 12 days old EHT from hiPSC-CM. B, Baseline contraction force (1.8 mM Ca2+) of spontaneously beating hiPSC-EHTs (n = 66) indicating the threshold value of 0.1 mN was reached for 65 hiPSC-EHTs. C, Calcium concentration–response-curve of hiPSC-EHTs (mean ± SEM; n = 11). D, Concentration–response-curve for isoprenaline (1 mM Ca2+, 2 Hz; n = 11). E, Positive inotropic and lusitropic effect in response to isoprenaline indicated as changes in force and relaxation time (RT; 100 nM; one-way ANOVA, repeated measures, Bonferroni’s post-test, *P < 0.05; n = 11). F, Time course of EHT development depicting contraction force overtime indicating stable EHT contractility starting at day 20 (mean ± SD; n = 12). G, Exemplary original trace of a human atrial trabecula in the organ bath demonstrating Frank–Starling mechanism, stable diastolic tension and robust contractions over initial equilibration period of 90 min.CC BY-NC · PubMed Central
Figure 2 Drug screening standard operating procedure (SOP). A, Long-term stability of the test systems. Time control data for contraction force and kinetics during analysis of hiPSC-EHT (left panel; red) and hAT (right panel; green). Please note that total incubation time varies between hiPSC-EHT (up to 240 min) and hAT (up to 30 min) with the same time window of 55 min highlighted in color. Repeated measures ANOVA with Dunnett’s post-test versus BL; *P < 0.05. B, Flow chart diagram of the SOP for cardiac drug screening on hiPSC-EHT.
Figure 2 Drug screening standard operating procedure (SOP). A, Long-term stability of the test systems. Time control data for contraction force and kinetics during analysis of hiPSC-EHT (left panel; red) and hAT (right panel; green). Please note that total incubation time varies between hiPSC-EHT (up to 240 min) and hAT (up to 30 min) with the same time window of 55 min highlighted in color. Repeated measures ANOVA with Dunnett’s post-test versus BL; *P < 0.05. B, Flow chart diagram of the SOP for cardiac drug screening on hiPSC-EHT.CC BY-NC · PubMed Central
Figure 3 Batch-to-batch variability. Contractile parameter of electrically stimulated hAT (A) and spontaneously beating hiPSC-EHTs (B, C). A, Human atrial trabeculae from 10 different patients electrically stimulated with 1 Hz (n = 52). B, HiPSC-EHTs from 5 different batches at days 12–22 post casting (n = 107). C, EHT contractility data divided by batch number (n = 9-19 per batch). Batch 5a–5c indicate three independent thawings and hiPSC-EHT generation from the same batch of cells. Note the larger scatter of contraction force in the hAT (A) versus hiPSC-EHT (B). See also Table 1. D, Transcriptome analysis of human nonfailing heart (NFH) and 3 batches (A–C) of hiPSC-CM in EHT-format showing heat map of gene expression normalized to housekeeping genes. Gene expression is expressed as log 10 values and color coded with high expression levels marked in green and low gene expression levels red. Batch B is split into three single EHTs of the same batch (B1, B2, B3) and batch C is split into three pools of 2–3 EHTs each (C1, C2, C3). Grey highlighted genes show significant variability in gene expression (≥log10 0.5 ≈ 3-fold) between the three hiPSC cell batches. See also Supplementary Table 2 for raw data and abbreviations of gene names.
Figure 3 Batch-to-batch variability. Contractile parameter of electrically stimulated hAT (A) and spontaneously beating hiPSC-EHTs (B, C). A, Human atrial trabeculae from 10 different patients electrically stimulated with 1 Hz (n = 52). B, HiPSC-EHTs from 5 different batches at days 12–22 post casting (n = 107). C, EHT contractility data divided by batch number (n = 9-19 per batch). Batch 5a–5c indicate three independent thawings and hiPSC-EHT generation from the same batch of cells. Note the larger scatter of contraction force in the hAT (A) versus hiPSC-EHT (B). See also Table 1. D, Transcriptome analysis of human nonfailing heart (NFH) and 3 batches (A–C) of hiPSC-CM in EHT-format showing heat map of gene expression normalized to housekeeping genes. Gene expression is expressed as log 10 values and color coded with high expression levels marked in green and low gene expression levels red. Batch B is split into three single EHTs of the same batch (B1, B2, B3) and batch C is split into three pools of 2–3 EHTs each (C1, C2, C3). Grey highlighted genes show significant variability in gene expression (≥log10 0.5 ≈ 3-fold) between the three hiPSC cell batches. See also Supplementary Table 2 for raw data and abbreviations of gene names.CC BY-NC · PubMed Central
Figure 4 Blinded drug screening of 10 compounds. Average contraction peaks. A, Average contraction peaks of electrically stimulated hiPSC-EHTs in modified Tyrode‘s solution (1.0 mM Ca2+) indicating relative force normalized to baseline over time. Four to eight EHTs per average peak. Black: baseline. Red: compound at indicated concentration (30 µM milrinone, 30 µM rolipram, 10 µM citalopram, 0.1 µM nifedipine, 30 µM lidocaine, 0.3 µM formoterol, 30 µM tacrolimus, 0.3 µM digoxin, 30 µM acetylsalicylic acid, 30 µM, and 0.3 µM [blue] ryanodine). B, Average contraction peaks of electrically stimulated hAT in modified Tyrode‘s solution (1.8 mM Ca2+). Four to six hAT per average peak. Black: baseline. Green: compound at indicated concentration (30 µM milrinone, 30 µM rolipram, 10 µM citalopram, 3 µM nifedipine, 30 µM lidocaine, 3 µM formoterol, 30 µM tacrolimus, 3 µM digoxin, 30 µM acetylsalicylic acid, 30 µM, and 3 µM [blue] ryanodine). Please note the different ordinate scale in the milrinone graph of the hAT measurement and the different concentrations of nifedipine, formoterol and digoxin in hiPSC-EHT versus hAT.
Figure 4 Blinded drug screening of 10 compounds. Average contraction peaks. A, Average contraction peaks of electrically stimulated hiPSC-EHTs in modified Tyrode‘s solution (1.0 mM Ca2+) indicating relative force normalized to baseline over time. Four to eight EHTs per average peak. Black: baseline. Red: compound at indicated concentration (30 µM milrinone, 30 µM rolipram, 10 µM citalopram, 0.1 µM nifedipine, 30 µM lidocaine, 0.3 µM formoterol, 30 µM tacrolimus, 0.3 µM digoxin, 30 µM acetylsalicylic acid, 30 µM, and 0.3 µM [blue] ryanodine). B, Average contraction peaks of electrically stimulated hAT in modified Tyrode‘s solution (1.8 mM Ca2+). Four to six hAT per average peak. Black: baseline. Green: compound at indicated concentration (30 µM milrinone, 30 µM rolipram, 10 µM citalopram, 3 µM nifedipine, 30 µM lidocaine, 3 µM formoterol, 30 µM tacrolimus, 3 µM digoxin, 30 µM acetylsalicylic acid, 30 µM, and 3 µM [blue] ryanodine). Please note the different ordinate scale in the milrinone graph of the hAT measurement and the different concentrations of nifedipine, formoterol and digoxin in hiPSC-EHT versus hAT.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 70

Metadata

Authors
Mannhardt, I., Eder, A., Dumotier, B., Prondzynski, M., Krämer, E., Traebert, M., Söhren, K.-D., Flenner, F., Stathopoulou, K., Lemoine, M. D., Carrier, L., Christ, T., Eschenhagen, T., & Hansen, A.
Affiliations
  • University Medical Center Hamburg-Eppendorf (DE)
  • Novartis (Switzerland) (CH)
  • Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
  • Universität Hamburg (DE)
Corresponding author
Hansen, Arne
Venue
Toxicological Sciences
Published
2017-04-27
Volume
158
Issue
1
Pages
164-175
ISSN
  • 1096-0929 (ISSN-L)
  • 1096-6080
OpenAlex
W2610084826
Cited by
68
References
59
Citations by year
2026: 2 · 2025: 4 · 2024: 13 · 2023: 8 · 2022: 7 · 2021: 6 · 2020: 13 · 2019: 12 · 2018: 3
FWCI
3.13
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Toxicological Sciences (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
German Centre for Cardiovascular Research
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
Keywords
hiPSC-derived cardiomyocytes, engineered heart tissue, lusitropic effect, cardiomyocyte contractility, drug testing, cAMP signaling, beta2-adrenergic agonists, phosphodiesterase III inhibitor, digoxin, tacrolimus, nifedipine, citalopram, lidocaine, formoterol, ryanodine, cardiomyocyte maturation
MeSH terms
Calcium, Heart Atria, Humans, Myocardial Infarction, Quality Control, Tissue Engineering, Myocytes, Cardiac, Induced Pluripotent Stem Cells, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.